AR064494A1 - Variantes de lipasa para uso farmaceutico - Google Patents
Variantes de lipasa para uso farmaceuticoInfo
- Publication number
- AR064494A1 AR064494A1 ARP070105859A ARP070105859A AR064494A1 AR 064494 A1 AR064494 A1 AR 064494A1 AR P070105859 A ARP070105859 A AR P070105859A AR P070105859 A ARP070105859 A AR P070105859A AR 064494 A1 AR064494 A1 AR 064494A1
- Authority
- AR
- Argentina
- Prior art keywords
- lipases
- lipase
- pharmaceutical use
- protease
- diabetes
- Prior art date
Links
- 239000004367 Lipase Substances 0.000 title abstract 6
- 102000004882 Lipase Human genes 0.000 title abstract 6
- 108090001060 Lipase Proteins 0.000 title abstract 6
- 235000019421 lipase Nutrition 0.000 title abstract 6
- 241000223258 Thermomyces lanuginosus Species 0.000 abstract 3
- 208000035467 Pancreatic insufficiency Diseases 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 2
- 239000004365 Protease Substances 0.000 abstract 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 230000029087 digestion Effects 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 239000004382 Amylase Substances 0.000 abstract 1
- 102000013142 Amylases Human genes 0.000 abstract 1
- 108010065511 Amylases Proteins 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 102000057297 Pepsin A Human genes 0.000 abstract 1
- 108090000284 Pepsin A Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 235000019418 amylase Nutrition 0.000 abstract 1
- 239000003833 bile salt Substances 0.000 abstract 1
- 229940093761 bile salts Drugs 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000001079 digestive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229940111202 pepsin Drugs 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87119606P | 2006-12-21 | 2006-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR064494A1 true AR064494A1 (es) | 2009-04-08 |
Family
ID=38043020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070105859A AR064494A1 (es) | 2006-12-21 | 2007-12-21 | Variantes de lipasa para uso farmaceutico |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8273348B2 (enExample) |
| EP (6) | EP2455460A3 (enExample) |
| JP (1) | JP5406040B2 (enExample) |
| KR (1) | KR20090101930A (enExample) |
| CN (2) | CN105112386A (enExample) |
| AR (1) | AR064494A1 (enExample) |
| AU (1) | AU2007337150A1 (enExample) |
| BR (1) | BRPI0721103A2 (enExample) |
| CA (3) | CA3081308C (enExample) |
| IL (1) | IL198893A0 (enExample) |
| MX (1) | MX2009006597A (enExample) |
| NO (1) | NO20092729L (enExample) |
| RU (1) | RU2009128067A (enExample) |
| TW (1) | TW200829698A (enExample) |
| WO (1) | WO2008079685A2 (enExample) |
| ZA (1) | ZA200903598B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5032300B2 (ja) | 2004-03-22 | 2012-09-26 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物 |
| EP1913138B1 (en) | 2005-07-29 | 2016-08-24 | Abbott Laboratories GmbH | Processes for the manufacture of pancreatin powder with low virus content |
| US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| JP5406040B2 (ja) * | 2006-12-21 | 2014-02-05 | ノボザイムス アクティーゼルスカブ | 医薬使用のためのリパーゼ変異体 |
| CA2716692A1 (en) | 2008-02-29 | 2009-09-03 | Dsm Ip Assets B.V. | Lipases with high specificity towards short chain fatty acids and uses thereof |
| AR070498A1 (es) * | 2008-02-29 | 2010-04-07 | Procter & Gamble | Composicion detergente que comprende lipasa |
| EP2250258B1 (en) | 2008-02-29 | 2017-01-04 | Novozymes A/S | Lipolytic enzyme variant with improved stability and polynucleotides encoding same |
| EP4159833A3 (en) | 2009-12-09 | 2023-07-26 | The Procter & Gamble Company | Fabric and home care products |
| DK2734633T3 (da) | 2011-07-22 | 2019-06-11 | Novozymes North America Inc | Fremgangsmåder til forbehandling af celluloseholdigt materiale og forbedring af hydrolyse deraf |
| US8268305B1 (en) | 2011-09-23 | 2012-09-18 | Bio-Cat, Inc. | Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase |
| CN110777016A (zh) * | 2011-12-29 | 2020-02-11 | 诺维信公司 | 具有脂肪酶变体的洗涤剂组合物 |
| MX391773B (es) * | 2012-02-03 | 2025-03-21 | Novozymes As | Variantes de lipasa y polinucleótidos que las codifican. |
| CN104204198B (zh) * | 2012-04-02 | 2018-09-25 | 诺维信公司 | 脂肪酶变体以及编码其的多核苷酸 |
| AU2013328953A1 (en) * | 2012-10-12 | 2015-03-26 | Danisco Us Inc. | Compositions and methods comprising a lipolytic enzyme variant |
| AR096270A1 (es) | 2013-05-14 | 2015-12-16 | Novozymes As | Composiciones detergentes |
| MX371497B (es) * | 2013-07-19 | 2020-01-31 | Danisco Us Inc | Composiciones y metodos que comprenden una variante de enzima lipolitica. |
| CN107075489A (zh) * | 2014-11-20 | 2017-08-18 | 诺维信公司 | 脂环酸芽孢杆菌变体以及编码它们的多核苷酸 |
| WO2016087401A1 (en) * | 2014-12-05 | 2016-06-09 | Novozymes A/S | Lipase variants and polynucleotides encoding same |
| MX382218B (es) | 2014-12-09 | 2025-03-13 | Novozymes As | Variantes de lipasa y polinucleotidos que las codifican. |
| US20180355404A1 (en) | 2015-04-07 | 2018-12-13 | Novozymes A/S | Methods for selecting enzymes having lipase activity |
| EP3317407B1 (en) * | 2015-07-01 | 2021-05-19 | Novozymes A/S | Methods of reducing odor |
| WO2017005640A1 (en) * | 2015-07-03 | 2017-01-12 | Novozymes A/S | Detergent compositions with improved stability in the presence of sulfites |
| CN109790525A (zh) | 2016-07-18 | 2019-05-21 | 诺维信公司 | 脂肪酶变体、编码其的多核苷酸及其用途 |
| JP7081767B2 (ja) * | 2017-01-30 | 2022-06-07 | 学校法人日本医科大学 | アデノ随伴ウイルス（ａａｖ）キャプシドタンパク質の変異体 |
| MX2020002964A (es) | 2017-09-27 | 2020-07-22 | Novozymes As | Variantes de lipasa y composiciones de microcapsula que comprenden las variantes de lipasa. |
| US11286443B2 (en) * | 2017-09-27 | 2022-03-29 | The Procter & Gamble Company | Detergent compositions comprising lipases |
| WO2019154955A1 (en) * | 2018-02-08 | 2019-08-15 | Novozymes A/S | Lipase variants and compositions thereof |
| US12269847B2 (en) * | 2018-08-16 | 2025-04-08 | Donaldson Company, Inc. | Genetically encoded polypeptide for affinity capture and purification of biologics |
| CN111334369B (zh) * | 2020-03-11 | 2022-10-21 | 陕西科技大学 | 一种酶法制备卵磷脂型pufa的方法 |
| JP7741827B2 (ja) * | 2020-06-24 | 2025-09-18 | シリアン アクチェンゲゼルシャフト | 新規リパーゼ酵素 |
| JP2023547450A (ja) * | 2020-10-29 | 2023-11-10 | ノボザイムス アクティーゼルスカブ | リパーゼ変異体及びそのようなリパーゼ変異体を含む組成物 |
| CN113846074B (zh) * | 2021-10-20 | 2022-10-21 | 南京林业大学 | 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用 |
| EP4525615A2 (en) | 2022-05-14 | 2025-03-26 | Novozymes A/S | Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections |
| EP4544015A2 (en) * | 2022-06-24 | 2025-04-30 | Novozymes A/S | Lipase variants and compositions comprising such lipase variants |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173590D0 (da) * | 1990-06-06 | 1990-07-19 | Novo Nordisk As | Rekombinante terapeutiske lipaser |
| DK0548228T3 (da) * | 1990-09-13 | 1999-05-10 | Novo Nordisk As | Lipasevarianter |
| DK46693D0 (enExample) * | 1993-04-23 | 1993-04-23 | Novo Nordisk As | |
| US5869438A (en) * | 1990-09-13 | 1999-02-09 | Novo Nordisk A/S | Lipase variants |
| ATE170630T1 (de) | 1990-12-05 | 1998-09-15 | Novo Nordisk As | Proteine mit geänderten epitopen und verfahren zur deren herstellung |
| FI934812L (fi) | 1991-05-01 | 1993-10-29 | Novo Nordisk As | Stabiliserade entzymer |
| DK39693D0 (da) | 1993-04-02 | 1993-04-02 | Novo Nordisk As | Enzym |
| AU7807394A (en) | 1993-10-04 | 1995-05-01 | Novo Nordisk A/S | An enzyme preparation comprising a modified enzyme |
| KR970701264A (ko) | 1994-02-22 | 1997-03-17 | 안네 제케르 | 지질분해효소의 변이체 제조방법(a method of preparing a viriant of a lipolytic enzyme) |
| EP0793726A1 (en) | 1994-11-24 | 1997-09-10 | Novo Nordisk A/S | A process for producing polypeptides with reduced allergenicity |
| CA2206852A1 (en) | 1994-12-07 | 1996-06-13 | Novo Nordisk A/S | Polypeptide with reduced allergenicity |
| DE69617641T3 (de) | 1995-01-26 | 2009-10-22 | Novozymes A/S | Xylanase beinhaltende futterzusätze für tiere |
| US6495357B1 (en) * | 1995-07-14 | 2002-12-17 | Novozyme A/S | Lipolytic enzymes |
| DE69633825T2 (de) | 1995-07-14 | 2005-11-10 | Novozymes A/S | Modifiziertes enzym mit lipolytischer aktivität |
| EP0851913B1 (en) | 1995-08-11 | 2004-05-19 | Novozymes A/S | Novel lipolytic enzymes |
| EP0954572A1 (en) | 1997-01-10 | 1999-11-10 | Novo Nordisk A/S | Enzyme coupled with polymeric molecules for skin care |
| WO1998035026A1 (en) | 1997-02-06 | 1998-08-13 | Novo Nordisk A/S | Polypeptide-polymer conjugates having added and/or removed attachment groups |
| CA2294567A1 (en) | 1997-06-25 | 1999-01-07 | Novo Nordisk A/S | A modified polypeptide |
| ATE328070T1 (de) * | 1998-02-17 | 2006-06-15 | Novozymes As | Lipasevariante |
| AU3247699A (en) | 1998-02-17 | 1999-09-06 | Novo Nordisk A/S | Lipase variant |
| CA2346929A1 (en) | 1998-10-13 | 2000-04-20 | Novozymes A/S | A modified polypeptide with reduced immune response |
| DE69916306T2 (de) | 1998-10-30 | 2005-05-04 | Novozymes A/S | Niedrigallergene proteinvarianten |
| WO2000026354A1 (en) | 1998-10-30 | 2000-05-11 | Novozymes A/S | Glycosylated proteins having reduced allergenicity |
| DK1131416T3 (da) | 1998-11-27 | 2009-10-26 | Novozymes As | Lipolytiske enzymvarianter |
| US7312062B2 (en) * | 1998-11-27 | 2007-12-25 | Novozymes A/S | Lipolytic enzyme variants |
| HK1044477B (zh) | 1999-03-17 | 2006-02-03 | Abbott Laboratories Gmbh | 治疗糖尿病的药物 |
| WO2000060063A1 (en) * | 1999-03-31 | 2000-10-12 | Novozymes A/S | Lipase variant |
| CA2366843A1 (en) * | 1999-03-31 | 2000-10-12 | Jesper Vind | Lipase variant |
| AU781415B2 (en) | 2000-02-08 | 2005-05-19 | Dsm Ip Assets B.V. | Use of acid-stable proteases in animal feed |
| AU2001254620A1 (en) * | 2000-04-28 | 2001-11-12 | Novozymes A/S | Lipolytic enzyme variant |
| EP1352057B1 (en) * | 2001-01-10 | 2009-03-25 | Novozymes A/S | Lipolytic enzyme variant |
| AR032392A1 (es) | 2001-01-19 | 2003-11-05 | Solvay Pharm Gmbh | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. |
| DE60233782D1 (de) | 2001-02-07 | 2009-11-05 | Novozymes As | Lipasevarianten |
| DK2295556T3 (en) | 2002-01-16 | 2015-01-26 | Novozymes As | Lipolytic Enzyme Variants and Method of Preparation thereof. |
| EP1592711A1 (en) | 2003-02-06 | 2005-11-09 | Novozymes A/S | Human heavy chain antibody expression in filamentous fungi |
| CA2523400C (en) * | 2003-05-09 | 2015-03-17 | Novozymes A/S | Variant lipolytic enzymes |
| EP1639107B1 (en) | 2003-06-19 | 2013-08-14 | Novozymes A/S | Improved proteases and methods for producing them |
| WO2004111216A2 (en) * | 2003-06-19 | 2004-12-23 | Novozymes A/S | Phospholipase variants |
| AU2005206251A1 (en) | 2004-01-21 | 2005-08-04 | Novozymes A/S | Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell |
| JP5032300B2 (ja) | 2004-03-22 | 2012-09-26 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物 |
| HUE031245T2 (en) | 2004-10-14 | 2017-06-28 | Lilly Co Eli | Preparations containing lipase, protease and amylase for the treatment of pancreatic insufficiency |
| EP1851311A2 (en) | 2005-02-10 | 2007-11-07 | Novozymes A/S | Enzymatic enantioselective ester or amide hydrolysis or synthesis |
| EP1896057A2 (en) | 2005-06-24 | 2008-03-12 | Novozymes A/S | Amylases for pharmaceutical use |
| CA2612648A1 (en) * | 2005-06-24 | 2006-12-28 | Novozymes A/S | Lipases for pharmaceutical use |
| JP2008546395A (ja) | 2005-06-24 | 2008-12-25 | ノボザイムス アクティーゼルスカブ | 医薬使用のためのプロテアーゼ |
| WO2007080197A2 (en) * | 2006-01-16 | 2007-07-19 | Novozymes A/S | Immobilised enzymes |
| DK1979477T3 (en) * | 2006-01-23 | 2017-06-26 | Novozymes As | lipase variants |
| JP2009523900A (ja) * | 2006-01-23 | 2009-06-25 | ザ プロクター アンド ギャンブル カンパニー | リパーゼと漂白剤触媒を含む組成物 |
| JP5406040B2 (ja) * | 2006-12-21 | 2014-02-05 | ノボザイムス アクティーゼルスカブ | 医薬使用のためのリパーゼ変異体 |
-
2007
- 2007-12-12 JP JP2009543078A patent/JP5406040B2/ja active Active
- 2007-12-12 EP EP12155315A patent/EP2455460A3/en not_active Withdrawn
- 2007-12-12 US US12/519,868 patent/US8273348B2/en active Active
- 2007-12-12 CA CA3081308A patent/CA3081308C/en active Active
- 2007-12-12 MX MX2009006597A patent/MX2009006597A/es not_active Application Discontinuation
- 2007-12-12 RU RU2009128067/10A patent/RU2009128067A/ru not_active Application Discontinuation
- 2007-12-12 AU AU2007337150A patent/AU2007337150A1/en not_active Abandoned
- 2007-12-12 EP EP10172609.9A patent/EP2261328B1/en active Active
- 2007-12-12 EP EP12155317.6A patent/EP2455461B1/en active Active
- 2007-12-12 EP EP07869130A patent/EP2099907A2/en not_active Withdrawn
- 2007-12-12 CN CN201510504893.8A patent/CN105112386A/zh active Pending
- 2007-12-12 CA CA2961041A patent/CA2961041C/en active Active
- 2007-12-12 CN CN200780051638.6A patent/CN101743308B/zh active Active
- 2007-12-12 WO PCT/US2007/087168 patent/WO2008079685A2/en not_active Ceased
- 2007-12-12 KR KR1020097014850A patent/KR20090101930A/ko not_active Withdrawn
- 2007-12-12 EP EP12155294.7A patent/EP2455459B1/en active Active
- 2007-12-12 CA CA2670643A patent/CA2670643C/en active Active
- 2007-12-12 BR BRPI0721103-1A patent/BRPI0721103A2/pt not_active IP Right Cessation
- 2007-12-12 EP EP12155319.2A patent/EP2455462B1/en active Active
- 2007-12-18 TW TW096148377A patent/TW200829698A/zh unknown
- 2007-12-21 AR ARP070105859A patent/AR064494A1/es not_active Application Discontinuation
-
2009
- 2009-05-21 IL IL198893A patent/IL198893A0/en unknown
- 2009-05-25 ZA ZA200903598A patent/ZA200903598B/xx unknown
- 2009-07-20 NO NO20092729A patent/NO20092729L/no not_active Application Discontinuation
-
2012
- 2012-08-16 US US13/587,043 patent/US9029115B2/en active Active
-
2015
- 2015-04-06 US US14/679,563 patent/US9539311B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064494A1 (es) | Variantes de lipasa para uso farmaceutico | |
| AR053634A1 (es) | Lipasas para uso farmaceutico | |
| Petrosino et al. | N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities | |
| ES2572160T3 (es) | Una nueva preparación farmacéutica para preeclampsia | |
| Shen et al. | Mutational analysis of structural features of rat hormone-sensitive lipase | |
| DK1755656T3 (da) | Enzymer til farmaceutisk anvendelse | |
| AR032392A1 (es) | Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado. | |
| AR119552A2 (es) | Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos | |
| Paula et al. | Modulation of the peroxiredoxin system by cytokines in insulin-producing RINm5F cells: down-regulation of PRDX6 increases susceptibility of beta cells to oxidative stress | |
| CY1118984T1 (el) | Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων | |
| EP4241854A3 (en) | Lysosomal storage disease enzyme | |
| JP2010512795A5 (enExample) | ||
| WO2005111008A3 (en) | Compounds for enzyme inhibition | |
| GB2497715A (en) | Preparation and use of combination enzyme and gastriontestinal modulator delivery systems | |
| AR063570A1 (es) | Efectos biologicos mejorados para composiciones que comprenden acido rosmarinico | |
| BR112012000914B8 (pt) | uso de polipeptídeo com atividade condrogênica, método in vitro de indução da diferenciação de células-tronco mesenquimais em condrócitos, e composição farmacêutica para aplicação intra-articular | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| Bhatta et al. | Angiotensin II-induced arterial thickening, fibrosis and stiffening involves elevated arginase function | |
| AR071261A1 (es) | Variantes de proteasa para uso farmaceutico | |
| BRPI0922653B8 (pt) | uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa | |
| Gidlöf | Toward a new paradigm for targeted natriuretic peptide enhancement in heart failure | |
| AR078291A1 (es) | Composiciones de enzimas pancreaticas y metodos para tratar pancreatitis e insuficiencia pancreatica | |
| Xiao et al. | The protein kinase C cascade regulates recruitment of matrix metalloprotease 9 to podosomes and its release and activation | |
| WO2006136160A3 (en) | Proteases for pharmaceutical use | |
| EP1961816A4 (en) | NEW HIGH-FUNCTIONAL ENZYME WITH MODIFIED SUBSTRATE SPECIFICITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |